Potential new drug effective in breast cancer, melanoma resistant to targeted therapies

LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 has showen promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies. Based on these preclinical results, several phase I clinical trials were launched recently.

Read the whole article on Science Daily

More from Science Daily